论文部分内容阅读
目的:观察不同病期、不同组织类型肺癌患者血清P53抗体、癌胚抗原水平单独与联合检测的结果,并比较其意义。方法:选择2000-01/2003-04在华北煤炭医学院附属开滦医院呼吸科、胸外科、肿瘤科住院的肺癌患者76例,男54例,女22例;年龄42～78岁。所有病例均确诊为肺癌,并同意参加此研究。鳞癌33例,腺癌23例,小细胞癌20例。早期肺癌23例,晚期肺癌53例。采用ELISA法检测肺癌患者血清P53抗体滴度,经酶联免疫检测仪测定吸光度值A450,计算P53抗体指数以判定血清P53抗体阴阳性。采用免疫分析仪检测癌胚抗原水平。阳性:P53抗体指数>0.428;癌胚抗原>10μg/L(正常值0～5μg/L)。阴性:P53抗体指数<0;癌胚抗原<0。结果:76例肺癌患者的血清P53抗体阳性率为49%(37/76)。单独检测:①早期肺癌患者血清P53抗体阳性率65%(15/23)明显高于癌胚抗原阳性率30%(7/23)(χ2=5.58,P<0.05);晚期肺癌P53抗体阳性率42%(22/53)与癌胚抗原阳性率28%(15/53)比较,差异无显著意义(P>0.05)。②鳞癌癌胚抗原阳性率15%(5/33)明显低于P53抗体阳性率48%(16/33)(χ2=8.45,P<0.01)。非小细胞癌癌胚抗原阳性率29%(16/56)明显低于P53抗体阳性率54%(30/56)(χ2=7.23,P<0.01)。联合检测:在早期肺癌中:P53抗体与癌胚抗原联合检测阳性率为78%(18/23)明显高于?
OBJECTIVE: To observe the results of single and combined detection of serum P53 antibody and carcinoembryonic antigen in patients with different types of lung cancer at different stages, and to compare their significance. Methods: A total of 76 patients with lung cancer who were hospitalized in Department of Respiratory, Thoracic and Oncology in Kailuan Hospital, North Kailuan Hospital, North China Coal Medical College from January 2000 to April 2003 were selected, including 54 males and 22 females, aged 42-78 years. All cases were diagnosed with lung cancer and agreed to participate in the study. 33 cases of squamous cell carcinoma, 23 cases of adenocarcinoma and 20 cases of small cell carcinoma. 23 cases of early lung cancer, 53 cases of advanced lung cancer. Serum P53 antibody titers were detected by ELISA in patients with lung cancer. The absorbance was measured by enzyme-linked immunosorbent assay (A450). The P53 antibody index was calculated to determine the positive and negative of serum P53 antibody. An immunoassay was used to detect the level of carcinoembryonic antigen. Positive: P53 antibody index> 0.428; carcinoembryonic antigen> 10μg / L (normal 0 ~ 5μg / L). Negative: P53 antibody index <0; carcinoembryonic antigen <0. Results: The positive rate of serum P53 antibody in 76 patients with lung cancer was 49% (37/76). The detection rate of P53 antibody in early stage of lung cancer was 65% (15/23), which was significantly higher than that of carcinoembryonic antigen (30/73) (χ2 = 5.58, P <0.05) There was no significant difference between 42% (22/53) and 28% (15/53) carcinoembryonic antigen (P> 0.05). ② The positive rate of SCC in squamous cell carcinoma was 15% (5/33), which was significantly lower than that of P53 antibody in 48% (16/33) (χ2 = 8.45, P <0.01). The positive rate of non-small cell carcinoma carcinoembryonic antigen was significantly lower than that of P53 antibody (29/56) (54/50) (χ2 = 7.23, P <0.01). Joint detection: in early lung cancer: P53 antibody and carcinoembryonic antigen detection rate was 78% (18/23) was significantly higher than?